These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 29111673

  • 1. Nano into Micro Formulations of Tobramycin for the Treatment of Pseudomonas aeruginosa Infections in Cystic Fibrosis.
    Porsio B, Cusimano MG, Schillaci D, Craparo EF, Giammona G, Cavallaro G.
    Biomacromolecules; 2017 Dec 11; 18(12):3924-3935. PubMed ID: 29111673
    [Abstract] [Full Text] [Related]

  • 2. Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
    Craparo EF, Porsio B, Schillaci D, Cusimano MG, Spigolon D, Giammona G, Cavallaro G.
    Nanomedicine (Lond); 2017 Jan 11; 12(1):25-42. PubMed ID: 27879162
    [Abstract] [Full Text] [Related]

  • 3. Nanometric ion pair complexes of tobramycin forming microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
    Sardo C, Di Domenico EG, Porsio B, De Rocco D, Santucci R, Ascenzioni F, Giammona G, Cavallaro G.
    Int J Pharm; 2019 May 30; 563():347-357. PubMed ID: 30935918
    [Abstract] [Full Text] [Related]

  • 4. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J, Abdelghany SM, Quinn DJ, Schmid D, Megaw J, Donnelly RF, Jones DS, Kissenpfennig A, Elborn JS, Gilmore BF, Taggart CC, Scott CJ.
    J Control Release; 2015 Jan 28; 198():55-61. PubMed ID: 25481442
    [Abstract] [Full Text] [Related]

  • 5. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD, Elborn JS.
    Expert Rev Respir Med; 2011 Oct 28; 5(5):609-22. PubMed ID: 21955231
    [Abstract] [Full Text] [Related]

  • 6. Polyester-based particles to overcome the obstacles of mucus and biofilms in the lung for tobramycin application under static and dynamic fluidic conditions.
    Ernst J, Klinger-Strobel M, Arnold K, Thamm J, Hartung A, Pletz MW, Makarewicz O, Fischer D.
    Eur J Pharm Biopharm; 2018 Oct 28; 131():120-129. PubMed ID: 30063969
    [Abstract] [Full Text] [Related]

  • 7. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
    Bahamondez-Canas TF, Zhang H, Tewes F, Leal J, Smyth HDC.
    Mol Pharm; 2018 Apr 02; 15(4):1643-1652. PubMed ID: 29514003
    [Abstract] [Full Text] [Related]

  • 8. Development, Characterization, and In Vitro Testing of Co-Delivered Antimicrobial Dry Powder Formulation for the Treatment of Pseudomonas aeruginosa Biofilms.
    Bahamondez-Canas TF, Ferrati S, Moraga-Espinoza DF, Smyth HDC.
    J Pharm Sci; 2018 Aug 02; 107(8):2172-2178. PubMed ID: 29698726
    [Abstract] [Full Text] [Related]

  • 9. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.
    Vazquez-Espinosa E, Marcos C, Alonso T, Giron RM, Gomez-Punter RM, Garcia-Castillo E, Zamora E, Cisneros C, Garcia J, Valenzuela C, Ancochea J.
    Expert Rev Anti Infect Ther; 2016 Aug 02; 14(1):9-17. PubMed ID: 26559549
    [Abstract] [Full Text] [Related]

  • 10. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis.
    Moreno-Sastre M, Pastor M, Esquisabel A, Sans E, Viñas M, Fleischer A, Palomino E, Bachiller D, Pedraz JL.
    Int J Pharm; 2016 Feb 10; 498(1-2):263-73. PubMed ID: 26705155
    [Abstract] [Full Text] [Related]

  • 11. Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin.
    Akkerman-Nijland AM, Yousofi M, Rottier BL, Van der Vaart H, Burgerhof JGM, Frijlink HW, Touw DJ, Koppelman GH, Akkerman OW.
    Ther Adv Respir Dis; 2020 Feb 10; 14():1753466620905279. PubMed ID: 32046620
    [No Abstract] [Full Text] [Related]

  • 12. Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis.
    Lababidi N, Ofosu Kissi E, Elgaher WAM, Sigal V, Haupenthal J, Schwarz BC, Hirsch AKH, Rades T, Schneider M.
    J Control Release; 2019 Nov 28; 314():62-71. PubMed ID: 31654686
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
    Lin Y, Chang RYK, Britton WJ, Morales S, Kutter E, Li J, Chan HK.
    Eur J Pharm Biopharm; 2019 Sep 28; 142():543-552. PubMed ID: 31398437
    [Abstract] [Full Text] [Related]

  • 15. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
    Somayaji R, Parkins MD.
    Ther Deliv; 2015 Feb 28; 6(2):121-37. PubMed ID: 25690082
    [Abstract] [Full Text] [Related]

  • 16. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
    Greenwood J, Schwarz C, Sommerwerck U, Nash EF, Tamm M, Cao W, Mastoridis P, Debonnett L, Hamed K.
    Ther Adv Respir Dis; 2017 Jul 28; 11(7):249-260. PubMed ID: 28614995
    [Abstract] [Full Text] [Related]

  • 17. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.
    Geller DE, Weers J, Heuerding S.
    J Aerosol Med Pulm Drug Deliv; 2011 Aug 28; 24(4):175-82. PubMed ID: 21395432
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Physical Characterization of Tobramycin Inhalation Powder: I. Rational Design of a Stable Engineered-Particle Formulation for Delivery to the Lungs.
    Miller DP, Tan T, Tarara TE, Nakamura J, Malcolmson RJ, Weers JG.
    Mol Pharm; 2015 Aug 03; 12(8):2582-93. PubMed ID: 26052676
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.